Galactomannan Does Not Precede Major Signs on a Pulmonary Computerized Tomographic Scan Suggestive of Invasive Aspergillosis in Patients with Hematological Malignancies by Weisser, M. et al.
Correlation of GM and Lung Infiltrates • CID 2005:41 (15 October) • 1143
M A J O R A R T I C L E
Galactomannan Does Not Precede Major
Signs on a Pulmonary Computerized Tomographic
Scan Suggestive of Invasive Aspergillosis in Patients
with Hematological Malignancies
M. Weisser,1 C. Rausch,1 A. Droll,2 M. Simcock,1,3 P. Sendi,1,3 I. Steffen,5 C. Buitrago,4 S. Sonnet,4 A. Gratwohl,2
J. Passweg,2 and U. Fluckiger1
1Division of Infectious Diseases and Hospital Epidemiology, 2Hematology, 3Basel Institute for Clinical Epidemiology, 4Department of Radiology,
and 5Institute of Medical Microbiology, University Hospital, Basel, Switzerland
Background. Detection of serum galactomannan (GM) antigen and presence of the halo sign on a pulmonary
computerized tomographic (CT) scan have a high specificity but a low sensitivity to diagnose invasive aspergillosis
(IA) in patients at risk for this disease. To our knowledge, the relationship between the time at which pulmonary
infiltrates are detected by CT and the time at which GM antigens are detected by enzyme immunoassay (EIA)
has not been studied.
Methods. In a prospective study, tests for detection of GM were performed twice weekly for patients with
hematological malignancies who had undergone hematopoetic stem cell transplantation (HSCT) or had received
induction and/or consolidation chemotherapy. A pulmonary CT scan was performed once weekly. Infiltrates were
defined as either major or minor signs. IA was classified as proven, probable, or possible, in accordance with the
definition stated by the European Organization for Research and Treatment of Cancer–Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Results. We analyzed 161 episodes of infection in 107 patients (65 allogeneic HSCT recipients, 30 autologous
HSCT recipients, and 66 induction and/or consolidation chemotherapy recipients). A total of 109 episodes with
no IA, 32 episodes with possible IA, and 20 episodes with probable or proven IA were identified. Minor pulmonary
signs were detected by CT in 70 episodes (43%), and major pulmonary signs were detected by CT in 11 episodes
(7%). Univariate and multivariate analyses revealed no significant association between detection of GM by EIA
and detection of abnormal pulmonary signs by CT. A significant association was found between GM levels and
receipt of piperacillin-tazobactam. GM test results were not positive before major signs were seen on CT images.
Only 7 (10%) of 70 patients with minor pulmonary signs had positive GM test results before detection of the
greatest pathologic change by CT.
Conclusions. We show that detection of GM by EIA does not precede detection of major lesions by pulmonary
CT. In the clinical setting, the decision to administer mold-active treatment should based on detection of new
pulmonary infiltrates on CT performed early during infection, rather than on results of EIA for detection of GM.
Invasive mold infections are increasing among patients
with hematological malignancies [1–5]. Incidences of
invasive aspergillosis (IA) as high as 12% have been
reported, with mortality rates of up to 80% [6–8]. The
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gold standards for the diagnosis of IA are positive re-
sults of culture of a sample obtained from a sterile site
or detection of hyphae by histopathologic or cytopath-
ologic examination of a biopsy specimen [9]. Sequential
thoracic CT scanning is a standard method used in the
diagnosis of IA. Early IA lesions are small, round, dense
areas that are typically located in the lung periphery
and increase in size over time. A halo sign on a CT
scan has been reported to be the first reliable sign of
infection, with a high specificity (93%) but a low sen-
sitivity (33%) [10]. Cavitation or air-crescent formation
occur later in the course of the disease and are usually
noted after bone marrow recovery [11–13].
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Table 1. Demographic and clinical characteristics of 107 pa-
tients who presented to the hematology ward with hematological





Age at study entry, median years (range) 48 (16–78)
Duration of hospitalization, median days (range) 29 (6–88)
Underlying disease
Acute myeloid leukemia 32 (29.9)
Acute lymphatic leukemia 21 (19.6)
Non-Hodgkin lymphoma 20 (18.7)
Myelodysplasia 13 (12.2)
Chronic myeloid leukemia 8 (7.5)
Multiple myeloma 6 (5.6)
Hodgkin lymphoma 3 (2.8)
Chronic lymphatic leukemia 3 (2.8)
Multiple sclerosis 1 (0.9)
No. of infection episodes 161
Therapy during hospitalization
Allogeneic stem cell transplantation 65 (40)
Autologous stem cell transplantation 30 (19)
High-dose chemotherapy 66 (41)
Neutropenia
Experienced a neutropenic episode during study 139 (86)
Duration of neutropenia, days
Median (range) 10 (0–56)
Total for all patients 1973
Total no. of galactomannan measurements 1418
NOTE. Data are no. (%) of patients, unless otherwise indicated.
Recently, serial testing for detection of galactomannan (GM)
antigen has been proposed as a screening tool for the diagnosis
of IA [14–16]. Whereas initial studies showed high sensitivities
and specificities for the GM test [17, 18], subsequent prospec-
tive studies primarily involving populations of patients with
hematological malignancy showed specificities of 85%–99% but
a broad range of sensitivities (29%–94%) [10, 19–25].
To standardize IA diagnoses for clinical research, a rating
system that classifies cases as possible, probable, and proven
on the basis of clinical, radiological, and microbiological criteria
(including results of GM tests [26]) was established by a panel
of experts from the European Organization for Research and
Treatment of Cancer–Invasive Fungal Infections Cooperative
Group and the National Institute of Allergy and Infectious
Diseases Mycoses Study Group (EORTC-MSG) [26]. However,
the rating system has not been evaluated as a guide for daily
clinical practice. Currently, patients at risk of developing IA
who do not respond to broad-spectrum antibiotic therapy and
who have thoracic CT scans that show a new infiltrate are
treated empirically with a mold-active drug [27, 28].
One study that evaluated the times to detection of GM by
ELISA and of pulmonary infiltrates by CT scanning showed
that IA could be diagnosed by detection of circulating GM a
mean duration of 8 days before diagnosis by other means [10].
However, this study was limited to patients who had recently
undergone allogeneic stem cell transplantation, and CT scans
were only performed for patients with a clinical suspicion of
invasive fungal infection. The purpose of our cohort study was
to analyze the time of onset of pulmonary lesions on CT images
obtained weekly and the time of detection of GM in serial EIA
of serum samples from all patients admitted to the hemato-
logical ward. In particular, we were interested in whether ele-
vated GM values preceded minor or major lesions observed on
CT scans of patients at risk for IA.
PATIENTS AND METHODS
We performed a prospective, single-cohort study that included
all adult patients who were admitted to the hematology ward
at the University Hospital in Basel, Switzerland, between May
2002 and September 2003 to undergo autologous or allogeneic
hematopoetic stem cell transplantation or to receive treatment
with induction and/or consolidation chemotherapy.
Monitoring of patients. Patients were investigated daily for
clinical symptoms of infection. Routine laboratory tests were
performed each day. At the onset of fever (defined as a tem-
perature of 138.5C) during the neutropenic stage, blood sam-
ples were obtained for culture, and broad-spectrum antibiotic
treatment that accorded with published guidelines [29] was
started. If a patient remained febrile for 172 h, an antifungal
agent (i.e., amphotericin B) was added to the treatment regi-
men. When infiltrates were detectable by CT, bronchoscopy
with bronchoalveolar lavage was performed. In the absence of
recovery of a specific pathogen, empirical voriconazole therapy
for Aspergillus infection was started.
Tests for detection of GM in serum were performed twice
weekly by use of the GM EIA (Platelia Aspergillus; BioRad
Laboratories) [18]. A total of 1418 GM tests were performed.
GM test results were interpreted as positive when an optical
density (OD) index of 0.5 was reached during 2 consecutive
measurements [30].
A pulmonary CT scan for each patient was performed rou-
tinely on a weekly basis or if clinically indicated. CT scans were
assessed a second time by a radiologist who was not involved
in the primary evaluation. Changes observed on CT images
were categorized as major signs (halos, crescent-signs, or cav-
ernous lesions) or as minor signs (all other infiltrates).
At the time of hospital discharge or death, episodes of pul-
monary infection were classified in terms of evidence for in-
vasive Aspergillus species. Cases of IA were classified according
to the EORTC/MSG definitions as proven, probable, or pos-
sible; patients without IA were classified as having no fungal
infection [26].
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Table 2. Pulmonary CT findings, galactomannan values, treatment, and outcome for 161 episodes of infection in 107 patients who
presented to the hematology ward with hematological malignancies between May 2002 and September 2003.
Infection
classification
Laboratory and clinical findings, proportion (%) of episodes Outcome, proportion (%) of patients













availableNo infiltrate Minor sign Major sign Mold active P-T
All 80/161 (50) 70/161 (43) 11/161 (7) 57/161 (35) 58/161 (36) 28/161 (17) 66/107 (62) 32/107 (30) 3/107 (3) 8/107 (7) 21/107 (20) 9/107 (8)
No IA 76/109 (70) 33/109 (30) 0 (0) 20/109 (18) 19/109 (17) 7/109 (6) 45/70 (64) 16/70 (23) 0 (0) 4/70 (6) 12/70 (17) 9/70 (13)
Possible IA 3/32 (9) 26/32 (81) 3/32 (10) 21/32 (65) 21/32 (65) 10/32 (31) 13/24 (54) 11/24 (46) 2/24 (8) 3/24 (13) 6/24 (25 ) 0 (0)
Probable or
proven IA 1/20 (5) 11/20 (55) 8/20 (40) 16/20 (80) 18/20 (90) 11/20 (55) 8/13 (62) 5/13 (38) 1/13 (7.5) 1/13 (7.5) 3/13 (23) 0 (0)
NOTE. GM, galactomannan antigenemia; IA, invasive aspergillosis (includes possible, probable, and proven cases, as defined by the European Organization
for Research and Treatment of Cancer–Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study
Group [26]); P-T, piperacillin-tazobactam.
a See Patients and Methods for the definition of GM test results.
Data on patient outcomes were collected from hematological
databases and categorized according to whether the patient had
survived without IA until the end of September 2003 or had
died. For patients who died, we noted whether an autopsy was
performed, and, if so, data regarding the presence of IA were
recorded.
Supportive-care measures. Each patient was hospitalized
in a single room in a hospital unit that was supplied with high-
efficiency particulate air filters. Antimicrobial prophylaxis dur-
ing hospitalization consisted of trimethoprim-sulfamethoxazole
(160 and 800 mg, respectively, 3 times weekly) and fluconazole
(400 mg once per week); patients infected with herpes simplex
virus also received either valacyclovir (two 500-mg doses twice
daily) or acyclovir (5 mg/kg twice daily).
Statistical analysis. Statistical analyses were performed
with SAS, version 8.2 (SAS Institute). Two different modeling
processes—univariate and multivariate—were adopted for data
analysis. We developed a univariate model with PROC GEN-
MOD (SAS Institute) and used a binomial distribution with a
logit link. To allow for multiple observations associated with
the same patient, the model was recalculated, incorporating the
measurements that were made more than once to produce the
multivariate model (i.e., a generalized estimating equations
[GEE] model that allowed correlation between repeated mea-
surements performed on the same patient). We used an un-
structured correlation/covariance matrix to permit direct pa-
rameterization in terms of variances and covariances. The
primary explanatory covariate of interest (CT finding) was
added to the model on both occasions. Collett’s procedure was
used to build the model, although no covariates other than the
use of piperacillin-tazobactam (P-T) were found to be statis-
tically significant for inclusion ( ). Potential confoundersP 1 .05
(age and sex) were then entered into the model. Fisher’s exact
test was used to compare patients who were and patients who
were not treated with P-T. P values of .01 were considered to
indicate statistical significance.
RESULTS
Patient population. A total of 161 episodes of infection oc-
curred in 107 patients admitted to the hematology ward, of
whom 66 (62%) were male and 41 (38%) were female. Patient
characteristics and underlying diseases are summarized in
table 1.
Analysis of thoracic CT findings, results of tests for detection
of GM, and clinical findings. In 80 (50%) of the 161 episodes,
no evidence of infiltrates was detectable on the CT scans at any
time during hospitalization (table 2). CT scanning revealed
minor signs in 70 episodes (43%) and major pathologic signs
in 11 episodes (7%) (usually in the form of a halo around a
nodular infiltrate). A total of 109 episodes (68%) were defined
as no IA, 32 episodes (20%) were defined as possible IA, and
20 episodes (12%) were defined as probable or proven IA,
according to EORTC/MSG criteria.
For the 2-week period before and the 2-week period after
the dates when the greatest pathological changes were observed
on CT scans, test results for detection of GM were positive on
2 consecutive occasions in 57 cases (35%). The percentage of
positive GM test results (i.e., 2 consecutive OD index mea-
surements of 0.5) was highest in the groups of patients clas-
sified as having probable or proven IA and lowest in the group
of patients defined as having no IA.
On the dates when CT revealed the greatest amount of path-
ological change, 58 patients (36%) were already receiving mold-
active therapy. The percentage of patients treated with a mold-
active agent on these dates was highest among those who were
classified as having a higher likelihood for IA.
A total of 66 (62%) of the 107 patients were alive at the end
of the study. Of these 66 patients, 45 showed no evidence of
IA, 13 showed evidence of possible IA, and 8 patients showed
evidence of probable or proven IA during hospitalization.
Thirty-two (30%) of the patients died. The mortality rate
was highest in the patient group classified as having possible
IA (46% [11 of 24 patients]), followed by the group with prob-
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Table 3. Comparison of galactomannan (GM) test results and pulmonary CT findings for
patients with hematological malignancies who were or were not receiving piperacillin-
tazobactam (P-T) at the time that the greatest pathological change was detected by CT.
Pulmonary
CT finding















No infiltrates 80 1 1 21 57
Minor signs 70 10 10 4a 46a
Major signs 11 4 2 1a 4a
NOTE. See Patients and Methods for the definition of GM test results.
a , by Fisher’s exact test.Pp .391
Table 4. Univariate and multivariate models of factors asso-







Minor sign vs. no infiltrate 1.12 (0.52–2.39) 1.09 (0.54–2.19)
Major sign vs. no infiltrate 2.54 (0.60–10.86) 2.47 (0.57–10.65)
P-T during CTa 3.60 (1.39–9.34) 3.70 (1.47–9.34)
Age 0.98 (0.96–1.01) …
Sex (male vs. female) 0.81 (0.40–1.66) …
NOTE. See Patients and Methods for the definition of GM test results.
Testing for detection of GM was performed within 2 weeks of pulmonary CT
scanning.
a Treatment with P-T at the time the greatest pathological change was de-
tected by CT.
able or proven IA (38% [5 of 13 patients]) and the group
without IA (23% [16 of 45 patients]).
Autopsies were performed for 11 of these patients. IA was
found to be present in 3 patients; 2 had been classified as having
possible IA, and 1 had been classified as having probable IA.
The intervals between clinical diagnosis of IA and autopsy for
these 3 patients were 12 and 14 weeks for the patients consid-
ered to have possible IA and 5 days for the patient considered
to have probable IA. Autopsy was performed for 5 of 11 patients
who had been classified as having possible IA during their
hospitalization and died before the end of the study. In 2 of
these patients, IA was proven histologically; IA was not found
in the other 3 patients.
Temporal sequence of positive results of GM tests and path-
ologic signs on CT scans. To investigate the relationship be-
tween detection of GM and the greatest pathological change
on CT scans, we analyzed 81 episodes to compare the courses
of GM test results with CT images revealing pathologic findings.
Of 70 episodes in which minor signs were observed, GM test
results were negative during the entire infection episode in 36
cases (51%); in 6 cases (9%), GM test results were positive at
the time that the greatest pathological change was revealed by
CT. In the remaining 28 episodes, a positive GM test result was
observed in 7 cases (10%) before a lesion appeared on a CT
scan, and a positive GM test results appeared in 21 cases (30%)
only after radiological signs had appeared on CT scans.
Of interest, 3 (27%) of 11 patients had major signs on pul-
monary CT scans and no positive GM test results throughout
the infection episode. All 3 patients were treated with antifun-
gals, and regression of pulmonary nodules was observed. In 1
patient, the lesion was surgically removed, and unspecific al-
veolitis was histologically diagnosed. Culture results remained
negative. The outcome for all 3 patients was favorable at the
end of the study. For 5 patients (45%), GM test results were
positive at the same time that pathologic signs were evident on
CT scans, and for 2 patients (18%), GM test results were pos-
itive only after the lesions had already appeared on CT scans.
For only 1 of these 11 patients, the OD value was 0.5 before
major pulmonary signs were detected by CT. However, this
patient was rehospitalized just 1 week after an episode in which
the first major signs appeared on CT scans, and thereafter, OD
values increased to 10.5.
Correlation of galactomannan antigenemia, P-T treatment,
and pulmonary infiltrates. Elevated levels of circulating GM
antigens resulting from the administration of P-T have been
recently described in the literature [31–33]. In 28 episodes of
infection (17%), antibiotic treatment with P-T was adminis-
tered at the time that the greatest pathological changes were
noted on CT scans. Table 3 organizes patients according to
positive or negative GM test results and receipt of P-T. Analysis
of patients who did not receive P-T revealed that pulmonary
findings for the group with positive GM test results were not
significantly different from those for the group with negative
GM test results ( , by Fisher’s exact test). Moreover,Pp .391
no significant difference among patients not treated with P-T
was observed regarding the presence or absence of any pul-
monary infiltrate ( , by Fisher’s exact test).Pp .70
Factors revealed by univariate and multivariate analyses
to be associated with positive GM test results. Univariate and
multivariate analyses were performed to evaluate the association
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between an OD of 0.5 and pathologic findings observed on
thoracic CT scans. In the univariate and multivariate analyses
adjusted for age and sex (in univariate analysis only) and P-T
use, major and minor signs on CT scans were not significantly
associated with positive GM test results (table 4). The associ-
ation between the detection of GM and the use of P-T was
statistically significant. Age and sex did not substantially influ-
ence estimates of the association between CT findings and GM
test results in the multivariate analyses (i.e., these characteristics
were not considered to be confounders) and were therefore not
included in the final multivariate model.
DISCUSSION
The EORTC/MSG criteria for establishing the diagnosis of pos-
sible, probable, or proven IA include the appearance of new
infiltrates on CT scans, positive results of an Aspergillus gal-
actomannan antigen test, and clinical signs of infection [26].
In the present study, we investigated the relationship between
temporal onset of pulmonary lesions on CT scans performed
weekly and EIA performed twice weekly for detection of GM.
We did not find that elevated ODs reliably preceded the ap-
pearance of nodular lesions with or without an accompanying
halo on CT scans. For patients treated with P-T, we could
confirm an association between this agent and serum EIAs with
elevated ODs. We cannot deduce the sensitivity and specificity
of the GM test on the basis of our results, because we included
all patients at high-risk for IA who were consecutively admitted
to the hematological ward (which reflects the daily clinical sit-
uation in our unit), rather than only patients with only probable
or proven cases of IA.
Major pulmonary signs on CT images have been reported
to be the earliest specific sign of infection in neutropenic pa-
tients [12, 13, 34]. We found major signs in 8 (40%) of 20
infection episodes classified as probable or proven IA but in
only in 3 (10%) of 32 episodes classified as possible IA. Minor
signs were most frequently associated with episodes classified
as possible IA (26 [81%] of 32 cases), followed by episodes
defined as probable or proven IA (11 [55%] of 20 cases). Un-
fortunately, minor signs on pulmonary CT scans can be caused
by many pathologic conditions, including those without infec-
tious causes, and such signs have a low specificity (6.6%), with
a sensitivity of 93% and positive and negative predictive values
of 50% [10].
Neither univariate nor multivariate analyses showed an as-
sociation between the time when the greatest pathological
change was observed on a CT scan and an elevated EIA OD,
even at a low cutoff value of 0.5. Of note, 3 (27%) of 11 patients
for whom a halo sign was present on a CT scan had a negative
result of a GM test (defined as an OD of !0.5) during the entire
episode of infection. Of the 70 patients with minor abnormal
CT findings, 36 (51%) had negative GM test results throughout
their episodes. The appearance of minor signs on CT scans was
preceded by elevated EIA ODs in only 7 episodes (10%). For
patients with major signs on CT scans, we found no elevated
EIA ODs preceding observance of the halo sign, which has been
reported to be an early specific sign of IA during the neutro-
penic stage [12].
Reasons for variation in circulating levels of GM might in-
clude administration of antifungal compounds or a low burden
of fungi [35–37]. In experimental animal models, it was shown
that antifungal treatment decreased or delayed GM detection
in serum [38, 39]. In several studies, antifungal prophylaxis
affected the sensitivity of the antigen test [23, 40]. In our study
population, patients received fluconazole prophylaxis, and
treatment was switched to either amphotericin B or voricon-
azole if a new pulmonary infiltrate appeared on the CT scan.
Overall, 58 patients (36%) were treated with a mold-active
agent at the time the greatest pathological changes were evident
on CT scans, which could, at least in part, explain the poor
association between elevated EIA ODs and radiological signs.
False-positive results of GM tests have been described for
patients who received P-T and/or other b-lactams [31–33, 41].
In our study, 20 of the 109 patients who were clinically classified
as having no IA had 2 consecutive EIA ODs of 0.5. P-T
therapy was administered to 14 of these 20 patients, which
could explain the false-positive test results. In univariate and
multivariate analyses adjusted for age and sex, concomitant
treatment with P-T was significantly associated with an elevated
EIA OD. One might argue that the large proportion of patients
receiving P-T in our study is a limitation of the results. How-
ever, in an analysis limited to patients who did not receive P-
T, we did not find a significant difference in pulmonary infil-
trate findings between the group with positive GM test results
and the group with negative GM test results.
A possible limitation of our study is that number of episodes
of probable or proven IA among our patients was small (20
cases [12%]). However, this number is comparable to findings
reported in other published studies [23]. Another limitation is
that the number of autopsies performed to confirm cases of
proven IA was limited, because autopsy was not performed for
all patients who died. On the other hand, if there is a long
interval between death and autopsy, the examination does not
necessarily give correct information about a prior fungal
infection.
One of the strengths of our study is the large number of
patients at risk for IA who had a long neutropenic phase. An-
other strength of the study is that we performed CT scans and
measured GM levels in serum samples at regularly defined in-
tervals and were therefore able to study the correlation between
GM levels and radiological signs on the CT scans longitudinally
and prospectively.
Our study shows that the first sign of possible IA or probable
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or proven IA is the observation of a new infiltrate on a CT
scan performed early during the disease course, followed by a
positive GM test result, which is needed to classify patients
according to the EORTC/MSG definitions. We could not ob-
serve an association between an elevated EIA OD and either
minor or major pulmonary signs on a CT image. In a hospital
setting where repeated performance of CT scans is possible,
clinicians should add drugs with activity against molds to the
broad-spectrum antibiotic regimen for selected high-risk pa-
tients as soon as a pulmonary nodular lesion is detected on a
CT scan.
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